WebJul 16, 2024 · About: Thiotepa (Thioplex®, Tepadina®) Thiotepa damages cancer cells through a process called alkylation. Alkylation damages the DNA of cells, which prevents them from dividing, and causes them to die. Since cancer cells, in general, divide faster and with less error-correcting than healthy cells, cancer cells are more sensitive to this damage. WebThe thiotepa solution is injected into the catheter, which is then removed. Normal walking around helps to disperse the medication throughout the bladder. The medication is left in for about 2 hours, after which the patient then empties the bladder (urinates). The amount of thiotepa that you will receive depends on many factors, including your ...
3374-MATRix (methotrexate cytarabine thiotepa …
WebNational Center for Biotechnology Information Web2.2. Use. Thiotepa is a cytostatic agent. It has been used in the treatment of lymphomas and a variety of solid tumours, such as those of breast and ovary; it has also been used in cases of urinary bladder malignancies, meningeal carcinomatosis and various soft-tissue tumours (Wright et al., 1958; Hollister & Coleman, 1980; Hagen et al., 1987; Reynolds, … hbl open on saturday
Thiotepa: Uses, Interactions, Mechanism of Action - DrugBank
WebMar 29, 2024 · Tepadina is used with other medicines before transplantation to destroy the abnormal cells and the patient’s existing blood-making cells. This allows new cells to be transplanted, by creating space for the new cells and reducing the risk of rejection. Thiotepa has been used to prepare patients for transplantation of blood-making cells in the ... WebDrugBank Accession Number. DB04572. Background. N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. WebJan 3, 2024 · De Jonge ME, Mathôt RA, Van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 2002; 50:251. English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal … h b l pak